P.E.T.Net pharmaceuticals licenses technology

Technology for labeling beta-amyloid plaques, which may be useful in detecting and treating Alzheimer’s disease, has been licensed from the University of California, Los Angeles by P.E.T.Net pharmaceuticals. The Knoxville, TN, company plans to use the technology to develop its own diagnostic tests, as well as to participate in research partnerships with pharmaceutical companies. The tests being developed will utilize positron-emitting molecular probes specific to the plaques and neural tangles associated with Alzheimer’s disease.